| Dr Anthony F Femminineo, MD | |
|
25311 Little Mack Ave, Suite B, St Clair Shores, MI 48081-3370 | |
| (586) 498-2400 | |
| (586) 498-2800 |
| Full Name | Dr Anthony F Femminineo |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 40 Years |
| Location | 25311 Little Mack Ave, St Clair Shores, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275527327 | NPI | - | NPPES |
| 1275527327 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 4301405128 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ascension St John Hospital | Detroit, MI | Hospital |
| Mclaren Macomb | Mount clemens, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Great Lakes Physiatrists Pc | 1153217278 | 13 |
News Archive
Cytokine PharmaSciences, Inc. today announced the completion of a Phase II study of the misoprostol vaginal insert (MVI), a proprietary, controlled-release and retrievable polymer chip containing prostaglandin E(1) (PGE1). Results of the dose-finding study in pregnant women at term gestation confirm the efficacy and safety of this investigational product and suggest that the MVI may reduce time to delivery after induction, support more natural labor, and reduce the rate of cesarean delivery.
BIBA Research, the UK-based market research specialists for the medical technology industry, announced today that the latest findings from their Transcatheter Heart Valve report will be released on 26 April. The report covers the data period January-March 2010 and is part of BIBA Research's long-established European Cardiovascular Monitor.
NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that researchers will present additional evidence for the potential utility of profiling breast cancer based on the PAM50 gene signature at the 2011 American Society of Clinical Oncology annual meeting taking place in Chicago, Illinois from June 3-7.
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that, following a recent meeting with the U.S. Food and Drug Administration (FDA) to discuss the Company's EMPOWER™ study results and the regulatory process, the Company intends to submit an Investigational Device Exemption (IDE) application for a clinical trial to support a possible Premarket Approval (PMA) application for the next-generation Maestro® RC System in the treatment of morbid obesity.
› Verified 7 days ago
| Entity Name | Great Lakes Physiatrists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811096548 PECOS PAC ID: 1153217278 Enrollment ID: O20040319000385 |
News Archive
Cytokine PharmaSciences, Inc. today announced the completion of a Phase II study of the misoprostol vaginal insert (MVI), a proprietary, controlled-release and retrievable polymer chip containing prostaglandin E(1) (PGE1). Results of the dose-finding study in pregnant women at term gestation confirm the efficacy and safety of this investigational product and suggest that the MVI may reduce time to delivery after induction, support more natural labor, and reduce the rate of cesarean delivery.
BIBA Research, the UK-based market research specialists for the medical technology industry, announced today that the latest findings from their Transcatheter Heart Valve report will be released on 26 April. The report covers the data period January-March 2010 and is part of BIBA Research's long-established European Cardiovascular Monitor.
NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that researchers will present additional evidence for the potential utility of profiling breast cancer based on the PAM50 gene signature at the 2011 American Society of Clinical Oncology annual meeting taking place in Chicago, Illinois from June 3-7.
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that, following a recent meeting with the U.S. Food and Drug Administration (FDA) to discuss the Company's EMPOWER™ study results and the regulatory process, the Company intends to submit an Investigational Device Exemption (IDE) application for a clinical trial to support a possible Premarket Approval (PMA) application for the next-generation Maestro® RC System in the treatment of morbid obesity.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Anthony F Femminineo, MD 8301 Reliable Parkway, Chicago, IL 60686-0083 Ph: (586) 498-2400 | Dr Anthony F Femminineo, MD 25311 Little Mack Ave, Suite B, St Clair Shores, MI 48081-3370 Ph: (586) 498-2400 |
News Archive
Cytokine PharmaSciences, Inc. today announced the completion of a Phase II study of the misoprostol vaginal insert (MVI), a proprietary, controlled-release and retrievable polymer chip containing prostaglandin E(1) (PGE1). Results of the dose-finding study in pregnant women at term gestation confirm the efficacy and safety of this investigational product and suggest that the MVI may reduce time to delivery after induction, support more natural labor, and reduce the rate of cesarean delivery.
BIBA Research, the UK-based market research specialists for the medical technology industry, announced today that the latest findings from their Transcatheter Heart Valve report will be released on 26 April. The report covers the data period January-March 2010 and is part of BIBA Research's long-established European Cardiovascular Monitor.
NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that researchers will present additional evidence for the potential utility of profiling breast cancer based on the PAM50 gene signature at the 2011 American Society of Clinical Oncology annual meeting taking place in Chicago, Illinois from June 3-7.
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that, following a recent meeting with the U.S. Food and Drug Administration (FDA) to discuss the Company's EMPOWER™ study results and the regulatory process, the Company intends to submit an Investigational Device Exemption (IDE) application for a clinical trial to support a possible Premarket Approval (PMA) application for the next-generation Maestro® RC System in the treatment of morbid obesity.
› Verified 7 days ago
Dr. Raymond T Bauer, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 25311 Little Mack Ave, Suite B, St Clair Shores, MI 48081 Phone: 586-498-2400 Fax: 586-498-2800 | |
Dr. Pano L Papalekas, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 25311 Little Mack, Ste B, St Clair Shores, MI 48081 Phone: 586-498-5400 Fax: 586-498-2800 | |
Dr. Stephen Wilson, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 24345 Harper Ave, St Clair Shores, MI 48080 Phone: 586-563-3300 Fax: 586-563-3313 | |
Dr. Joseph P Femminineo, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 25311 Little Mack Ave, Suite B, St Clair Shores, MI 48081 Phone: 586-498-2400 Fax: 586-498-2800 | |
Dr. Frank S Pollina, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 25311 Little Mack Ave, Ste B, St Clair Shores, MI 48081 Phone: 586-498-2400 Fax: 586-498-2800 |